Skip to main content
Equibles
HRTX logo

HRTX · Heron Therapeutics, Inc. /De/

Track HRTX — free

Use HRTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about HRTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.34 +0.00 (+0.69%) At close · Aug 14
Market Cap
$63.92M
Shares
189.85M

Heron Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Heron Therapeutics, Inc. (HRTX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲23.1% $27.63M −$56.36M '22 Q2 22-08-09 ▲14.3% $26.56M −$41.91M '22 Q3 22-11-08 ▲26.3% $29.61M −$32.77M '23 Q1 23-05-11 ▲15% $31.76M −$42.06M '23 Q2 23-08-14 ▲18.4% $31.43M −$25.01M '23 Q3 23-11-14 ▲14% $34.23M −$10.72M '23 Q4 24-03-12 ▲17.1% $34.67M −$3.16M '24 Q1 24-05-07 ▲13.4% $36.02M −$9.23M '24 Q2 24-08-06 ▲4.4% $32.81M −$4.85M '24 Q3 24-11-12 ▲19.1% $40.78M $3.66M '24 Q4 25-02-27 ▲12.2% $38.90M $2.63M '25 Q1 25-05-06 ▲3.3% $37.20M −$2.38M '25 Q2 25-08-08 ▲16.5% $38.21M −$17.50M '25 Q3 25-11-04 ▼0.5% $40.59M −$2.95M '25 Q4 26-02-26 ▼10.8% $34.71M −$8.11M '26 Q1 26-05-11 LATEST ▲1.3% $37.67M −$5.49M '26 Q2 26-08-10
Earnings call
FY26 · Q2
2026-08-10
Heron Therapeutics Q2 2026 Conference Call
Revenue
$37.67M
▲ 1.3% YoY
Diluted EPS
$-0.03
Gross margin
69.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Heron Therapeutics, Inc. /De/ Q1 FY2026 Earnings Call
Positive tone Crosslink / Ignite Partnership Oncology / Sinvanti Acute Care Portfolio Growth
Revenue
$34.71M
▼ 10.8% YoY
Diluted EPS
$-0.04
▼ 500% YoY
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Heron Therapeutics, Inc. /De/ Q4 FY2025 Earnings Call
Confident tone Acute care franchise momentum No Pain Act reimbursement awareness PONV consensus guidelines
Revenue
$40.59M*
▼ 0.5% YoY
Gross margin
72.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Heron Therapeutics, Inc. /De/ Q3 FY2025 Earnings Call
Confident tone Acute care growth (ZYNRELEF and APONVIE) CINVANTI stability PONV guidelines inclusion
Revenue
$38.21M
▲ 16.5% YoY
Diluted EPS
$-0.10
Gross margin
68.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-08
Heron Therapeutics, Inc. /De/ Q2 FY2025 Earnings Call
Confident tone ZYNRELEF commercial performance ZYNRELEF reimbursement and access APONVIE growth
Revenue
$37.20M
▲ 3.3% YoY
Diluted EPS
$-0.02
Gross margin
73.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Heron Therapeutics, Inc. /De/ Q1 FY2025 Earnings Call
Confident tone APONVIE adoption in hospitals ZYNRELEF growth and market expansion CINVANTI / oncology franchise performance
Revenue
$38.90M
▲ 12.2% YoY
Diluted EPS
$0.01
Gross margin
78.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Heron Therapeutics, Inc. /De/ Q4 FY2024 Earnings Call
Confident tone ZYNRELEF Growth and Inflection CINVANTI Competition and Pricing Risk CrossLink Partnership
Revenue
$40.78M*
▲ 19.1% YoY
Gross margin
74.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Heron Therapeutics, Inc. /De/ Q3 FY2024 Earnings Call
Confident tone ZYNRELEF Growth Drivers (VAN, NOPAIN, CrossLink) CINVANTI Recovery and 340B Opportunity APONVIE Commercial Trajectory
Revenue
$32.81M
▲ 4.4% YoY
Diluted EPS
$-0.03
Gross margin
71.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Heron Therapeutics, Inc. /De/ Q2 FY2024 Earnings Call
Confident tone ZYNRELEF label expansion and catalysts CrossLink partnership and sales force expansion Vial Access Needle (VAN) PDUFA
Revenue
$36.02M
▲ 13.4% YoY
Diluted EPS
$-0.06
Gross margin
70.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Heron Therapeutics, Inc. /De/ Q1 FY2024 Earnings Call
Confident tone CrossLink partnership and sales force expansion ZYNRELEF label expansion and product performance Vial Access Needle (VAN) device development
Revenue
$34.67M
▲ 17.1% YoY
Diluted EPS
$-0.02
Gross margin
75.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
Heron Therapeutics, Inc. /De/ Q4 FY2023 Earnings Call
Confident tone Vial Access Needle and Prefilled Syringe development ZYNRELEF growth and label expansion No Pain Act and reimbursement
Revenue
$34.23M*
▲ 14% YoY
Gross margin
71.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Heron Therapeutics, Inc. /De/ Q3 FY2023 Earnings Call
Revenue
$31.43M
▲ 18.4% YoY
Diluted EPS
$-0.17
Gross margin
42.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Heron Therapeutics, Inc. /De/ Q2 FY2023 Earnings Call
Revenue
$31.76M
▲ 15% YoY
Diluted EPS
$-0.35
Gross margin
36.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Heron Therapeutics, Inc. /De/ Q1 FY2023 Earnings Call
Revenue
$29.61M
▲ 26.3% YoY
Diluted EPS
$-0.27
Gross margin
43.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q3
2022-11-08
Heron Therapeutics, Inc. /De/ Q3 FY2022 Earnings Call
Revenue
$26.56M
▲ 14.3% YoY
Diluted EPS
$-0.38
Gross margin
44.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Heron Therapeutics, Inc. /De/ Q2 FY2022 Earnings Call
Revenue
$27.63M
▲ 23.1% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Heron Therapeutics, Inc. /De/ Q1 FY2022 Earnings Call
Revenue
$23.46M
▲ 17.2% YoY
Diluted EPS
$-0.63
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Heron Therapeutics, Inc. /De/ Q4 FY2021 Earnings Call
Revenue
$20.66M*
▲ 0.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Heron Therapeutics, Inc. /De/ Q3 FY2021 Earnings Call
Revenue
$23.23M
▲ 16.4% YoY
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Heron Therapeutics, Inc. /De/ Q4 FY2020 Earnings Call
Revenue
$20.61M
▼ 41.3% YoY
Gross margin
54.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY19 · Q4
2020-01-13
Heron Therapeutics, Inc. /De/ Q4 FY2019 Earnings Call
Revenue
$35.08M
▲ 21.6% YoY
Gross margin
54.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–21 of 21 earnings calls
Key facts CIK 818033 CUSIP 427746102 13F (30d) 154 filings 154 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)